Alkermes Aktie - Fundamentalanalyse - Dividendenrendite KGV

Alkermes (ISIN: IE00B56GVS15, WKN: A1JKVH) Kursdatum: 18.05.2018 Kurs: 46,270 USD
Beschreibung Daten
Symbol ALKS
Marktkapitalisierung 7.098.511.872,00 USD
Land Irland
Indizes NASDAQ Comp.
Sektor Chemie
Rohdaten nach US GAAP in Millionen USD
Aktiensplits 2000-05-15 - 2.0000/1.0000 |
Internet www.alkermes.com
Letztes Bilanz Update 17.02.2018

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 18.05.2018
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
-221,07 369,91 0,00% -8,79 66,93 -44,92 7,86 5,90

Firmenbeschreibung

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company\'s marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr. Quellen: www.bundesanzeiger.de, www.sec.gov, www.alkermes.com